What are the adverse effects of sunitinib in the treatment of renal cell carcinoma (RCC)?

Updated: Jun 08, 2020
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

Major toxicities (grade II or higher) of sunitinib include fatigue (38%), hypothyroidism (in as many as 30%), diarrhea (24%), nausea (19%), dyspepsia (16%), stomatitis (19%), and decline in cardiac ejection fraction (11%). Dermatitis occurred in 8%, and hypertension occurred in 5% of patients.

Hypertension induced by sunitinib may correlate with a significantly higher probability of response and better disease-free and overall survival. [34] Likewise, onset of hypothyroidism in patients treated with sunitinib may portend better response. [35]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!